Zamaporvint is under clinical development by Redx Pharma and currently in Phase II for Metastatic Biliary Tract Cancer. According to GlobalData, Phase II drugs for Metastatic Biliary Tract Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Zamaporvint LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RXC-004 is under development for the treatment of pancreatic ductal adenocarcinoma, metastatic biliary tract cancer, intrahepatic and extrahepatic cholangiocarcinoma, gallbladder cancer, metastatic colorectal cancer, pancreatic cancer, gastric cancer and biliary tumor. It is administered orally. The drug candidate targets protein cysteine N palmitoyltransferase porcupine of the Wnt pathway. The drug candidate is developed based on Redox Switch technology. It was under development for the treatment of melanoma.
Redx Pharma overview
Redx Pharma, formerly Redx Pharma is a drug discovery and development company that develops early stage and small molecule therapeutics. The company’s major pipeline products include RXC004, RXC007, RXC008, DDR, RXC006/AZD5055, JZP815, among other drug candidates. Its drug products are used for the treatment of pancreatic cancer, idiopathic pulmonary fibrosis (IPF), fibro stenotic crohn’s disease, oncology and fibrosis, and Fibrosis, Cancer-associated fibrosis. Redx Pharma’s redox switch is also used for delivering multiple development candidates over mechanistic approaches in the treatment of cancer. The company conducts research through its facilities in the UK. Redx Pharma is headquartered in Macclesfield, the UK.
For a complete picture of Zamaporvint’s drug-specific PTSR and LoA scores, buy the report here.